CJC-1295 Side Effects: Cardiovascular and Endocrine Safety Risks
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue marketed for anti-aging, body composition, and performance, but it is not FDA-approved for any of these uses. The FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction, and states available clinical data are limited.
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue marketed for anti-aging, body composition, and performance, but it is not FDA-approved for any of these uses. The FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction, and states available clinical data are limited.
Key Takeaways
- CJC-1295 is not FDA-approved for anti-aging, bodybuilding, or wellness use.
- The FDA has identified serious adverse events, including increased heart rate and a systemic vasodilatory reaction, and notes clinical data are limited.
- It stimulates the GH/IGF-1 axis, so cardiovascular, glucose, fluid-retention, and endocrine effects are central concerns.
- People with heart disease, hypertension, diabetes, a cancer history, or endocrine disorders are especially unsuitable for unsupervised use.
- Disclose any CJC-1295 use to your clinicians, and check it against your full medication list with the Allmeds drug checker.
CJC-1295 at a Glance
| Property | Detail |
|---|---|
| Type | Synthetic growth-hormone-releasing hormone (GHRH) analogue |
| FDA approval status | Not approved for anti-aging, body composition, or performance use |
| Promoted uses | Anti-aging, muscle gain, fat loss, recovery, none are FDA-approved |
| Mechanism | Stimulates the growth hormone / IGF-1 axis |
| Evidence base | Limited clinical data; FDA-identified serious adverse events |
| Compounding status | FDA category: substances with potential significant safety risks |
| Key FDA concern | Increased heart rate and systemic vasodilatory reaction |
CJC-1295 Side Effects: What Is Known
Because CJC-1295 has not undergone the controlled human trials required for approval, its side-effect profile is not well characterised. The concerns below follow from its growth-hormone-axis mechanism and from adverse events the FDA has flagged.
| Side Effect Domain | What May Occur | Why It Matters |
|---|---|---|
| Cardiovascular | Rapid heart rate, palpitations, flushing, vasodilation, dizziness, fainting | FDA has specifically identified increased heart rate and systemic vasodilatory reaction |
| Fluid retention / edema | Swelling, headache | Common to GH/IGF-1 stimulation |
| Glucose intolerance | Raised blood sugar | GH-axis stimulation can impair glucose regulation |
| Nerve symptoms | Numbness or tingling (carpal-tunnel-like) | Fluid and GH-axis effects can compress nerves |
| Immune / allergic | Rash, swelling, injection-site infection, anaphylaxis | Peptide impurities can trigger immune reactions; FDA notes immunogenicity risk |
| Long-term effects | Unknown | No long-term human safety studies exist |
Taking CJC-1295 alongside other medications?
Check it against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
Safety Profile in Detail
| Dimension | Research summary |
|---|---|
| Mechanism | CJC-1295 stimulates the GH/IGF-1 axis. Potential adverse effects may relate to GH/IGF-1 stimulation, fluid retention, glucose effects, and cardiovascular responses. |
| Clinical evidence | FDA safety-risk listing and sports-medicine reviews indicate limited clinical data and concern about serious adverse events. |
| Severity | Moderate to potentially serious, especially for cardiovascular symptoms, glucose intolerance, edema, cancer history, or endocrine disorders. |
| Symptoms to watch | Palpitations, rapid heart rate, flushing, dizziness, fainting, swelling, headache, numbness or tingling, high glucose, or injection-site infection. |
| Official guidance | FDA identifies potential immunogenicity, impurity/API concerns, increased heart rate, systemic vasodilatory reactions, and limited clinical data. |
| Practical patient advice | Avoid non-prescribed CJC-1295. People with heart disease, hypertension, diabetes, cancer history, or endocrine disease are especially unsuitable for unsupervised exposure. |
Common Questions About CJC-1295 Side Effects
It is not FDA-approved for anti-aging, bodybuilding, or wellness use.
Rapid heart rate, flushing/vasodilation, edema, glucose changes, and allergic reactions are concerning.
It is designed to stimulate the GH/IGF-1 axis, which is also why endocrine risks matter.
FDA has identified safety concerns for compounded CJC-1295, including limited data and serious adverse events.
People with cardiovascular disease, diabetes, active cancer, endocrine disorders, pregnancy, or uncertain diagnosis should avoid unsupervised use.
Check CJC-1295 against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. fda.gov.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- European Medicines Agency. Product information and EPARs. ema.europa.eu.